Download MendeleyY06014 is a selective BET inhibitor for the treatment of prostate cancer.
Wu, T.B., Xiang, Q.P., Wang, C., Wu, C., Zhang, C., Zhang, M.F., Liu, Z.X., Zhang, Y., Xiao, L.J., Xu, Y.(2021) Acta Pharmacol Sin 42: 2120-2131
- PubMed: 33654218
- DOI: https://doi.org/10.1038/s41401-021-00614-7
- Primary Citation of Related Structures:
7DHS - PubMed Abstract:
Bromodomain and extra-terminal proteins (BETs) are potential targets for the therapeutic treatment of prostate cancer (PC). Herein, we report the design, the synthesis, and a structure-activity relationship study of 6-(3,5-dimethylisoxazol-4-yl)benzo[cd]indol-2(1H)-one derivative as novel selective BET inhibitors. One representative compound, 19 (Y06014), bound to BRD4(1) in the low micromolar range and demonstrated high selectivity for BRD4(1) over other non-BET bromodomain-containing proteins. This molecule also potently inhibited cell growth, colony formation, and mRNA expression of AR-regulated genes in PC cell lines. Y06014 also shows stronger activity than the second-generation antiandrogen enzalutamide. Y06014 may serve as a new small molecule probe for further validation of BET as a molecular target for PC drug development.
Organizational Affiliation:
College of Science, Key Laboratory of Rare-earth Chemistry and Applying of Liaoning Province, Shenyang University of Chemical Technology, Shenyang, 110142, China.
